[Possibility of using TFX (thymus factor X) in the treatment of systemic lupus erythematosus].
A case of a 32-year female patient with the systemic lupus erythematosus is presented. The patient was treated with prednisone in a daily dose of 40-60 mg. Due to the exacerbations of the symptoms and advanced renal disorders, the patient was given TFX together with corticotherapy. Thymus factor X is an extract of real thymus of immunorecorrective properties. It specifically acts on the lymphatic system, especially disordered mechanisms of both cellular and humoral immunity. Thymus factor X was given in the dose of 10 mg (one ampoule) i.m. for the three first months followed by one ampoule every three days for the next three months. The patient is given one ampoule of TFX once a week since the 6th months of therapy. Diminishment of the symptoms was observed. The patient is in remission since a one-year follow-up period. It was also possible to reduce the dose of prednisone to 15 mg a day. The patient is controlled every 3 months. Partial normalization of renal functioning and immunological mechanisms are seen. A decrease in antinuclear antibodies and immunoglobulins, normalization in complement components, an increase in T-cells percentage and conversion of the delayed skin reaction are noted. The authors conclude that TFX may be helpful in the treatment of the autoimmunological diseases, including the systemic lupus erythematosus.
Lasisz
B
B
Zdrojewicz
Z
Z
Dul
W
W
Markiewicz
A
A
Strychalski
J
J
D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; C019108:TFX; D013949:Thymus Extracts
Mozliwość zastosowania preparatu TFX (thymus factor X) w leczeniu tocznia układowego.